N@N

Geoff Meacham Maintained (BIIB) at Hold with Increased Target to $300 on, Apr 21st, 2023

Geoff Meacham of B of A Securities, Maintained "Biogen Inc." (BIIB) at Hold with Increased Target from $295 to $300 on, Apr 21st, 2023.

Geoff has made no other calls on BIIB in the last 4 months.

There are 11 other peers that have a rating on BIIB. Out of the 11 peers that are also analyzing BIIB, 1 agrees with Geoff's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $263 on, Monday, April 17th, 2023

These are the ratings of the 10 analyists that currently disagree with Geoff

---

• Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $346 on, Monday, April 17th, 2023
• Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $320 on, Monday, April 17th, 2023
• Matthew Korn of "Morgan Stanley" Maintained at Buy with Decreased Target to $349 on, Wednesday, April 12th, 2023
• Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $325 on, Tuesday, April 11th, 2023
• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $325 on, Thursday, March 23rd, 2023
• Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $333 on, Thursday, February 16th, 2023
• Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $340 on, Thursday, February 16th, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $351 on, Thursday, February 16th, 2023
• Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $310 on, Thursday, February 16th, 2023
• Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $315 on, Thursday, February 16th, 2023

Contributing Sources

---